This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (33)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Aging/ Geriatrics  • Evidence-Based Medicine  • Hypertension  • Alert me on articles by topic

Can Better Care Cost Less?

Michael A. Fischer, MD, MS; Jerry Avorn, MD

JAMA. 2004;291:1850-1856.

Context  Deviation from evidence-based guidelines in hypertension treatment is common, but its economic impact has not been rigorously studied. Suboptimal prescribing patterns contribute to the high cost of medications for elderly patients as well as the difficulty in providing affordable prescription drug benefits for older Americans.

Objective  To calculate the potential savings from the perspective of health care payers that would result from increased adherence to evidence-based recommendations for managing hypertension in patients older than 65 years.

Design  Comparative analysis of medications prescribed vs potential regimens suggested by evidence-based guidelines tailored to each patient's medical history, with calculation of the costs of both the actual and the evidence-based regimens.

Setting and Patients  A total of 133 624 patients being treated for hypertension during 2001 who were enrolled in a large state pharmaceutical assistance program that provides prescription drug insurance for elderly persons.

Main Outcome Measure  Cost difference between medications actually prescribed and regimens suggested by evidence-based guidelines.

Results  The patients studied filled more than 2.05 million prescriptions for antihypertensive medications in 2001, at an annual program cost of $48.5 million ($363 per patient). We identified 815 316 prescriptions (40%) for which an alternative regimen appeared more appropriate according to evidence-based recommendations. Such changes would have reduced the costs to payers in 2001 by $11.6 million (nearly a quarter of program spending on antihypertensive medications), as well as being more clinically appropriate overall. Replacement of calcium channel blockers resulted in the largest potential savings. Use of pricing limits similar to those in the Medicaid program would have resulted in even larger potential savings of $20.5 million (42% of program costs).

Conclusions  Adherence to evidence-based prescribing guidelines for hypertension could result in substantial savings in prescription costs for elderly patients with hypertension that would amount to savings of about $1.2 billion nationally. Identification of similar areas in which prescribing can be improved will be critical for the affordability of prescription drug benefit programs.

Author Affiliations: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Call to Action on Use and Reimbursement for Home Blood Pressure Monitoring: A Joint Scientific Statement From the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association
Pickering et al.
Hypertension 2008;52:10-29.
ABSTRACT | FULL TEXT  

Ambulatory Blood Pressure Measurement: The Case for Implementation in Primary Care
O'Brien
Hypertension 2008;51:1435-1441.
FULL TEXT  

Pharmaceutical Promotion to Physicians and First Amendment Rights
Kesselheim and Avorn
NEJM 2008;358:1727-1732.
FULL TEXT  

The International Pharmaceutical Market as a Source of Low-Cost Prescription Drugs for U.S. Patients
Kesselheim and Choudhry
ANN INTERN MED 2008;148:614-619.
ABSTRACT | FULL TEXT  

Extensions Of Intellectual Property Rights And Delayed Adoption Of Generic Drugs: Effects On Medicaid Spending
Kesselheim et al.
Health Aff (Millwood) 2006;25:1637-1647.
ABSTRACT | FULL TEXT  

GI Risk Factors and Use of GI Protective Agents Among Patients Receiving Nonsteroidal Antiinflammatory Drugs
Harris et al.
The Annals of Pharmacotherapy 2006;40:1924-1931.
ABSTRACT | FULL TEXT  

Changes in Antihypertensive Prescribing During US Outpatient Visits for Uncomplicated Hypertension Between 1993 and 2004
Ma et al.
Hypertension 2006;48:846-852.
ABSTRACT | FULL TEXT  

Long-Term and Short-Term Changes in Antihypertensive Prescribing by Office-Based Physicians in the United States
Stafford et al.
Hypertension 2006;48:213-218.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Ambulatory Blood Pressure: A Reanalysis
Krakoff
Hypertension 2006;47:29-34.
ABSTRACT | FULL TEXT  

Direct-to-Consumer Advertising of COX-2 Inhibitors: Effect on Appropriateness of Prescribing
Spence et al.
Med Care Res Rev 2005;62:544-559.
ABSTRACT  

Hypertension in Adults Across the Age Spectrum: Current Outcomes and Control in the Community
Lloyd-Jones et al.
JAMA 2005;294:466-472.
ABSTRACT | FULL TEXT  

High and Rising Health Care Costs. Part 4: Can Costs Be Controlled While Preserving Quality?
Bodenheimer and Fernandez
ANN INTERN MED 2005;143:26-31.
ABSTRACT | FULL TEXT  

Torcetrapib and Atorvastatin -- Should Marketing Drive the Research Agenda?
Avorn
NEJM 2005;352:2573-2576.
FULL TEXT  

Diuretic based therapy reduced CV mortality in older patients with isolated systolic hypertension and diabetes
Alkhenizan
Evid. Based Med. 2005;10:75-75.
FULL TEXT  

Improving the quality of health care: using international collaboration to inform guideline programmes by founding the Guidelines International Network (G-I-N)
Ollenschlager et al.
Qual Saf Health Care 2004;13:455-460.
ABSTRACT | FULL TEXT